SUNDAY, MAY 20, 2018

Cerus, SunCoast Blood Bank agree to use of INTERCEPT platelets, plasma

SunCoast Blood Bank (SCBB) recently signed a three-year purchase plan to use platelets and plasma from Cerus Corporation's INTERCEPT Blood System.

The INTERCEPT Blood System is specially designed to ensure that blood is safe and clean. The technology uses nucleic acid to target known transfusion threats, including hepatitis B and C, malaria, dengue fever, West Nile virus, HIV, and similar pathogens, decreasing the risk of infections originating from transfusions.

SCBB collects more than 45,000 units of blood products each year. This includes more than 5,500 plasma units and 6,000 platelets units. All of these units are used to support 12 different hospitals in southwest Florida.

SCBB is the first blood center in Florida that provides INTERCEPT-treated components, which are used in transfusions and similar medical treatments. 

Cerus produces biomedical products that pertain to blood safety. The company markets the INTERCEPT Blood System’s plasma and platelets in the U.S., Europe, the Middle East and other areas around the world.

“We are proud to be working with a progressive blood center such as SunCoast, to positively impact patient lives through the implementation of INTERCEPT pathogen reduction technology,” William 'Obi' Greenman, Cerus’ president and chief executive officer, said. “In addition to reduced transfusion transmission risk, we believe INTERCEPT will offer the added benefit of early platelet release, thereby increasing platelet units’ effective shelf life, and providing SunCoast the flexibility to offer its hospitals fresher platelets for improved patient outcomes.”